Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture

Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martínez A

Authors: Herrera-Martínez A, Van Dungen R, Van Koetsveld P, Dogan-Oruc F, Culler M,

Keywords: NETs, somatostatin receptors, dopamine receptors, multi-receptor targeting drugs, hormone secretion,

#2135 Is the Classification of Functioning-PanNET/Non-Functioning PanNET Properly? Insulinoma/Non-Insulinoma Is More Suitable to Distinguish the Clinicopathological and Prognosis Difference of Localized Insulinoma

Introduction: Pancreatic neuroendocrine tumor (PanNET) is classified into Functioning (F-PanNET) and Non-functioning (NF-PanNET) by hormone secretion. But insulinoma is slowly proliferating with unique features compared with Non-insulinoma F-PanNET (NiF-PanNET).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: yu x

Authors: Gao H, Yu X,

Keywords: pancreatic neuroendocrine tumor, insulinoma, functionality, prognosis, Ki-67,

#1915 Interactions between SSTR Modulation via Lanreotide and Molecular Targeted Therapies in Sequential and Combination Approaches in Vitro

Introduction: SSA represent the standard of care for controlling symptoms of patients with functional GEP-NEN and have anti-proliferative effects. Molecular targeted therapies (MTT) against angiogenesis resulted in an increased PFS, however, due to primary and acquired resistance to MTT, the impact on OS remains unclear. One of the most pivotal questions, whether combining SSA with novel MTT will result in enhanced anti-proliferative activity compared to monotherapy treatment, are lacking.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Krug S

Authors: Krug S, Gress T, Theuerkorn K, Mordhorst J, Michl P,

Keywords: SSA, targeted therapies, SSTR,

#1467 iFiT: An Integrative Bioinformatics Platform for Biomarker and Target Discovery. A Case Study in Neuroendocrine Tumors

Introduction: iFiT (Ipsen Focused-on-new bIological enTities and biomarkers) is a Bioinformatics platform integrating systems biology functionalities together with semantic & logic-based artificial intelligence within a high-scale computing environment.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Tourlet S

Authors: Tourlet S, Scaerou F, Martin A, Thiagalingam A, Paty I,

Keywords: Targets iFiT,

#780 Epigenetic Regulation of Endogenous Somatostatin Expression in Neuroendocrine Tumors

Introduction: Somatostatin (SST) can regulate hormone secretion and cell proliferation in neuroendocrine tumors (NETs). SST expression levels in NETs likely differ between patients. DNA methylation inhibits gene transcription and can be reversed by the demethylating drug 5-aza-2-deoxycytidine (AZA).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Veenstra M, Van Koetsveld P, Dogan F, Waaijers A, Sprij-Mooij D,

Keywords: somatostatin, epigenetics,